Diabetes Research Institute Foundation, Inc.
Diabetes Research Institute Foundation, Inc.
Want to make a donation using Daffy?
Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.
Do you work for Diabetes Research Institute Foundation, Inc.? Learn more here.
By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.
About this organization
Mission
The Mission of the Diabetes Research Institute Foundation is to provide the Diabetes Research Institute with funding necessary to cure diabetes now.
About
The Diabetes Research Institute Foundation funds basic, pre-clinical and patient-based research studies, including five Phase I/II clinical studies, several of which are simultaneously underway at the Diabetes Research Institute (DRI), with the others pending commencement. The ongoing 'islets in the omentum' BioHub trial was the first step in testing the safety and efficacy of insulin-producing cells transplanted within a tissue-engineered platform in a different site than the liver, the traditional transplant site. Foundation funding has allowed the DRIs clinical cell transplant team to contact and screen more than 1,200 candidates for this innovative pilot trial, several of whom were selected and placed on the waiting list to undergo the procedure pending the availability of a matching donor organ. Other alternative transplant sites continue to be explored. DRIF funding also supports the continued follow-up and care of the DRIs islet transplant patients who have participated in previous clinical trials. Many of these have remained insulin independent for a varying number of years. This past year, DRI presented data showing that their islet transplant patients who were still free from insulin for an average of 10 years had near-normal blood sugar levels, similar to those without diabetes. DRIF has also funded DRI research projects that focus on establishing immune tolerance and reversing autoimmunity, the bodys destruction of the insulin-producing cells which caused the onset of the disease. Several of the clinical trials address these challenges while other research earlier in the pipeline remains underway. Another major research area that DRIF supports is the development of an unlimited supply of insulin-producing cells. DRIF-funded studies have led to significant progress in stimulating the regeneration of pancreatic stem cells into insulin-producing cells using a single FDA-approved molecule. This significant finding opens to door to a natural cell supply bank within the patients body, addressing several ongoing challenges for curing the disease. The DRIF has funded international researcher training and key collaborative programs that help accelerate research progress through the sharing of ideas and advancements. Also, DRIF-funded research equipment was used in a Phase III multi-center clinical islet transplantation trial. The resulting data demonstrated that islet transplantation is effective in preventing severe hypoglycemia dangerously low blood sugar levels which represents a particularly feared complication in type 1 diabetes that can lead to seizures, loss of consciousness and even death. Importantly, the results of this Phase III trial pave the way for islet transplantation to become an FDA-approved treatment for patients with diabetes and one that would be eligible for insurance reimbursement. Key funded research areas include cell-based therapies for islet replacement, immune tolerance, immune regulation, regenerative medicine, and stem cell research, among others, to restore biological insulin production. Together with other diabetes advocacy organizations, the DRIF has appeared before Congress to request increased funding for diabetes research, and has made recommendations on the future direction of research appropriations. DRIF also hosts and participates in a variety of informational workshops for people with diabetes and their families focusing on the latest advances toward a cure and the newest diabetes management techniques. Through its website DiabetesResearch.org, the DRIF provides 'news you can useresearch updates for those living with diabetes and their family members in the form of e-newsletters, videos, email announcements and information via social media.
Interesting data from their 2020 990 filing
The non-profit's mission, as described in the filing, is “To provide the diabetes research institute with the funding necessary to cure diabetes now.”.
When describing its duties, they were characterized as: “To provide the diabetes research institute with the funding necessary with the funding to cure diabetes now.”.
- The non-profit has complied with legal regulations by reporting their state of operation as FL.
- The filing shows that the non-profit's address as of 2020 is 200 South Park Rd Suite 100, Hollywood, FL, 33021.
- As of 2020, the non-profit has reported a total of 36 employees on their form.
- Does not operate a hospital.
- Does not operate a school.
- Does not collect art.
- Does not provide credit counseling.
- Does not have foreign activities.
- Is not a donor-advised fund.
- Is not a private foundation.
- Expenses are greater than $1,000,000.
- Revenue is greater than $1,000,000.
- Revenue less expenses is -$1,764,028.
- The compensation of the CEO of the organization is subject to review and approval by an independent body.
- The organization has a written policy that describes how long it will retain documents.
- The organization has a foreign financial account.
- The organization has 24 independent voting members.
- The organization has a professional fund raiser.
- The organization was formed in 1974.
- The organization has a written policy that addresses conflicts of interest.
- The organization is required to file Schedule B.
- The organization is required to file Schedule J.
- The organization is required to file Schedule O.
- The organization engages in lobbying activities.
- The organization pays $2,171,816 in salary, compensation, and benefits to its employees.
- The organization pays $1,989,300 in fundraising expenses.
- The organization provides Form 990 to its governing body.
- The organization has minutes of its meetings.
- The organization has a written whistleblower policy.
- The organization has fundraising events.
- The organization has grants to organizations.
- The organization's financial statements were reviewed by an accountant.